Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer

Clinical Gynecologic Oncology: Eighth Edition

Volumn , Issue , 2012, Pages 121-139

  Landrum, Lisa M ^a   Zuna, Rosemary E ^b   Walker, Joan L ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902032186     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-07419-3.00004-7     Document Type: Chapter

References (234)

1. Chamlian DL, Taylor HB Endometrial hyperplasia in young women. Obstet Gynecol 1970, 36:659.
2. Cherkis RC, Patten SF, Dickinson JC, et al. Significance of atypical endometrial cells detected by cervical cytology. Obstet Gynecol 1987, 69:786.
3. Emge LA Endometrial cancer and feminizing tumors of the ovary. Obstet Gynecol 1953, 1:511.
4. Fechner RE, Kaufman RH Endometrial adenocarcinoma in Stein-Leventhal syndrome. Cancer 1974, 34:444.
5. Gallup DG, Stock RJ Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984, 64:417.
6. Jaakola S, Lyytinen H, Pukkala E, et al. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009, 114:1197.
7. Lyon FA, Frisch MJ Endometrial abnormalities occurring in young women on long-term sequential oral contraception. Obstet Gynecol 1976, 47:639.
8. Merriam JC, Easterday CL, Mckay CL, et al. Experimental production of endometrial cancer in the rabbit. Obstet Gynecol 1960, 16:253.
9. Pettersson B, Bergstrom R, Johansson EDB Serum estrogens and androgens in women with endometrial carcinoma. Gynecol Oncol 1986, 25:223.
10. Weiss NS, Szekely DR, Austin DF Increasing incidence of endometrial cancer in the United States. N Engl J Med 1976, 294:1259.
11. Wood GP, Boronow RC Endometrial adenocarcinoma and the polycystic ovary syndrome. Am J Obstet Gynecol 1976, 124:140.
12. Baak JP, Mutter GL, Robboy S, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005, 103:2304.
13. Bhagavan BS, Parmley TH, Rossenshein NB, et al. Comparison of estrogen-induced hyperplasia to endometrial carcinoma. Obstet Gynecol 1984, 64:12.
14. Creasman WT Estrogen replacement therapy: Is previously treated cancer a contraindication?. Obstet Gynecol 1984, 64:12.
15. Ferenczy A, Bergeron C Endometrial hyperplasia. Advances in Gynecological Pathology 1992, 207. Churchill Livingstone, London. D. Lowe, H. Fox (Eds.).
16. Ferenczy A, Gelfand MM, Tzipris F, et al. The cytodynamics of endometrial hyperplasia and carcinoma: a review. Ann Pathol 1983, 3:189.
17. Fox H, Buckley CH The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopathology 1982, 6:493.
18. Gusberg SB Precursors of corpus carcinoma, estrogens, and adenomatous hyperplasia. Am J Obstet Gynecol 1947, 54:905.
19. Gusberg SB, Hall RE Precursors of corpus cancer. III: The appearance of cancer of the endometrium in estrogenically-conditioned patients. Obstet Gynecol 1961, 17:397.
20. Gusberg SB, Kaplan AL Precursors of corpus cancer. Am J Obstet Gynecol 1963, 87:662.
21. Gusberg SB, Moore DB, Martin F Precursors of corpus cancer. II: A clinical and pathological study of adenomatous hyperplasia. Am J Obstet Gynecol 1954, 68:1472.
22. Hertig AT, Sommerd SC Genesis of endometrial carcinoma: study of prior biopsy. Cancer 1949, 2:946.
23. Ingram JM, Novak E Endometrial carcinoma associated with feminizing ovarian tumors. Am J Obstet Gynecol 1951, 61:774.
24. Jackson RL, Dockerty MB The Stein-Leventhal syndrome analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol 1957, 73:161.
25. Kraus FT High-risk and premalignant lesions of the endometrium. Am J Surg Pathol 1985, 9:31.
26. Kurman RJ, Kalminski PF, Norris HJ The behavior of endometrial hyperplasia: a long term study of "untreated" hyperplasia in 170 patients. Cancer 1985, 56:403.
27. Kurman RJ, Norris HJ Endometrial hyperplasia and metaplasia. Blaustein's Pathology of the Female Genital Tract 1987, Springer Verlag, New York. R.J. Kurman (Ed.).
28. Kurman RJ, Norris HJ Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated. carcinoma. Cancer 1982, 49:2547.
29. Maxwell GL, Risinger JI, Grumbs C, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 1998, 58:2500.
30. Mutter GL, Lin M, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000, 92:924.
31. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992, 16:600.
32. Silverberg SG Hyperplasia and carcinoma of the endometrium. Semin Diagn Pathol 1988, 5:135.
33. Silverberg SG Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol 2000, 13:309.
34. Spiegel GW Endometrial carcinoma in situ in post-menopausal women. Am J Surg Pathol 1995, 19:417.
35. Sturdee DW, Wade-Evans T, Paterson ME, et al. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. Br Med J 1978, 1:1575.
36. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006, 106:812.
37. Trimble CL, Kauderer J, Silverberg S, Curtin J, Lim PC, Burke JJ, Zaino R Concurrent endometrial cancer (EC) in women with biopsy diagnosis of atypical endometrial hyperplasia (AEH): A Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2004, 92:393.
38. Welch WR, Scully RE Precancerous lesions of the endometrium. Hum Pathol 1977, 8:503.
39. Wright TC, Schiffman M, Solomon D, et al. Interim Guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004, 103:304.
40. Winkler B, Alvarez S, Richart RM, et al. Pitfalls in the diagnosis of endometrial neoplasia. Obstet Gynecol 1984, 64:185.
41. Zaino RJ Endometrial hyperplasia: Is it time for a quantum leap to a new classification?. Inter J Gynecol Path 2000, 19:314.
42. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, Gallup DG The reproducibility of the diagnosis of atypical Endometrial Hyperplasia (AEH): a Gynecologic Oncology Group Study. Cancer 2006, 106:804.
43. Bonte J, Decoster JM, Ide P, et al. Hormonoprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate. Gynecol Oncol 1978, 6:60.
44. Bullock JL, Massey FM, Gambrell RD Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975, 46:165.
45. Buttini MJ, Jordan SJ, Webb PM The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust NZ J Obstet Gynaecol 2009, 49(3):316.
46. Cade TJ, Quinn MA, Rome RM, et al. Progestogen treatment options for early endometrial cancer. BJOG 2010, Apr 12. Epub.
47. Chin J, Konje JC, and Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev Oct 7;(4):CD007245, 2009.
48. Chiva LM, Lapuente F Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 2008, 111(2 suppl):S101.
49. Chu J, Schweid AI, Weiss NS Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. Am J Obstet Gynecol 1982, 143:569.
50. Gal D, Edman CD, Vellios F, et al. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 1983, 146:316.
51. Rigg LA, Hermann H, Yen SS Absorption of estrogens from vaginal creams. N Engl J Med 1978, 298:195.
52. Steiner GJ, Kistner RW, Craig JM Histological effects of progestin on hyperplasia and carcinoma in situ of the endometrium: further observations. Metabolism 1965, 14:356.
53. Varma TR Effect of long-term therapy with estrogen and progesterone on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand 1985, 64:41.
54. Wilson PA, Kolstad P Hormonal Treatment of Preinvasive and Invasive Carcinoma of the Corpus Uteri in Endometrial Cancer 1973, William Heinemann Medical Books, London.
55. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005, 352:1851.
56. North American Menopause Society Role of progestogen in hormone therapy for postmenopausal women: position statement of the North American Menopause Society. Menopause 2003, 10:113.
57. Walsh CS, Blum A, et al. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Gynecol Oncol 2010, 116:516.
58. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995, 85:304.
59. Kurman RJ, Felix JC, Archer DF, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000, 96:3733.
60. Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2000, 186:651.
61. Raudaskoski T, Papanainen J, Tomas E, et al. Intrauterine 10 μg and 20 levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2000, 109:136.
62. The Writing Group for the PEPI Trial Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA 1996, 275:370.
63. Wildemeersch D, Dhont M Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003, 188:1297.
64. Writing Group for the Women's Health Initiative Investigators; Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002, 288:321.
65. Anderson JJ, Ferguson DJP, Raab GH Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 1982, 46:376.
66. Antunes CMF, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use: report of a large case-control study. N Engl J Med 1979, 300:9.
67. Baker DP Estrogen replacement therapy in patients with a previous diagnosis of endometrial carcinoma. Compr Ther 1990, 16:28.
68. Banrabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005, 105:1063.
69. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy verses placebo in stage I or II endometrial cancer: a gynecologic oncology group study. J Clin Oncol 2006, 24:587.
70. Blumel J, Castelo-Branco C, Chedraudi P, et al. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 2004, 11:57.
71. Boston Collaborative Drug Surveillance Program, Boston University Medical Center Surgical confirmed gall-bladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974, 290:15.
72. Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996, 175:1195.
73. Christiansen C, Christiansen MS, Transbol I Bone mass in postmenopausal women after withdrawal of oestrogen/progestogen replacement therapy. Lancet 1981, 1:459.
74. Creasman WT, Henderson D, Hinshaw W, et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Cancer 1986, 67:326.
75. Fremont-Smith M, Meigs JW, Graham RM, et al. Cancer of the endometrium and prolonged estrogen therapy. JAMA 1946, 131:805.
76. Gabrielsson J, Wallenback I, Birgerson L Pharmacokinetic data on estradiol in light of the Estring® concept. Acta Obstet Gynecol Scand Suppl 1996, 163:25.
77. Gambrell RD Preventing endometrial cancer with progestins. Contemp Obstet Gynecol 1981, 17:133.
78. Gordon GE, Greenberg BG Exogenous estrogen and endometrial cancer: an invited review. Postgrad Med 1976, 59:67.
79. Gray LA, Christopherson WM, Hoover RN Estrogens and endometrial carcinoma. Obstet Gynecol 1977, 49:385.
80. Gusberg SB, Kardon P Proliferative endometrial response to thecal granulosa cell tumors. Am J Obstet Gynecol 1971, 3:633.
81. Heart Disease and Stroke Statistics-2010 Update, American Heart Association.
82. Henderson BE, Ross RK, Paganini-Hill A Estrogen use and cardiovascular disease. J Reprod Med 1985, 30:814.
83. Hendrikson L, Stjernquist M, Boquist L, et al. A one-year multicenter study of efficacy and safety of a continuous low-dose, estradiol-releasing vaginal ring (Estring®) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996, 174:85.
84. Hoogerlan DL, Buchler DA, Crowley JJ, et al. Estrogen use: risk of endometrial carcinoma. Gynecol Oncol 1978, 64:451.
85. Hoover R, Gray LA, Cole P, et al. Menopausal estrogens and breast cancer. N Engl J Med 1976, 295:401.
86. Horowitz RI, Feinstein AR Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978, 299:1089.
87. Horowitz RI, Feinstein AR Susceptibility bias and the estrogen-endometrial cancer controversy (Abstract). Clin Res 1979, 27:222A.
88. Kampman E, Potter JD, Slattery ML, et al. Hormone replacement therapy, reproductive history and colon cancer: a multicenter, case-control study in U.S. Cancer Causes Control 1997, 8:146.
89. Kay CR Progestogens and arterial disease: evidence from the Royal College of General Practitioners' study. Am J Obstet Gynecol 1982, 142:762.
90. Killacke MA, Halkes TB, Pierce VK Endometrial endocarcinoma in breast cancer patients receiving anti-estrogens. Cancer Threat Rep 1985, 69:237.
91. Kistner RW Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer 1959, 12:1106.
92. Lee RB, Burke TW, Park RC Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990, 36:189.
93. Lyon FA The development of adenocarcinoma of the endometrium in young women receiving long-term sequential oral contraception. Am J Obstet Gynecol 1975, 123:299.
94. MacDonald PC, Siiteri PK The relationship between the extraglandular production of estrone and the occurrence of endometrial neoplasia. Gynecol Oncol 1974, 2:259.
95. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976, 294:1262.
96. Mansell H, Hertig AT Granulosa-theca cell tumor and endometrial carcinoma: A study of their relationship and survey of 80 cases. Obstet Gynecol 1955, 6:385.
97. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349(6):523.
98. Maxwell GL, Tian C, Risinger JI, et al. Racial disparities in recurrence among patients with early stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy. Cancer 2008, 113:1431.
99. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy. I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979, 53:277.
100. Naessen T, Rodriquez-Macias K Endometrial thickness and uterine diameter not affected by ultralow doses of 17β estradiol in elderly women. Am J Obstet Gynecol 2002, 186:944.
101. NIH State-of-the-Science Panel; National Institutes of Health state-of-the-science conference statement management of menopause-related symptoms. Annals of Intern Med 2005, 142(12):1003.
102. NAMS September 8, 2005. Use of Testosterone Therapy by Post menopausal Women: Position Statement of the North American Menopausal Society. Menopause Sept/Oct 2005. The role of testosterone in postmenopausal women".
103. Pacheco JC, Kempers RD Etiology of postmenopausal bleeding. Obstet Gynecol 1968, 32:40.
104. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293.
105. Riggs BL, Jowsey J, Goldsmith RS, et al. Short and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis. J Clin Invest 1972, 51:1659.
106. Rosenwaks Z, Wentz AC, Jones GS, et al. Endometrial pathology and estrogens. Obstet Gynecol 1979, 53:403.
107. Shapiro S, Kelly JP, Rosenberg L Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985, 313:968.
108. Silverberg SQ, Makowski EL Endometrial carcinoma in young women taking oral contraceptives. Obstet Gynecol 1975, 46:503.
109. The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701, 2004.
110. Weiss NS, Sayretz TA Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980, 302:551.
111. Woodruff DJ, Pickar JH Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterones or conjugated estrogens alone. Am J Obstet Gynecol 1994, 170:1213.
112. Writing Group for the Women's Health Initiative Investigators: Risks and benefits if estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321.
113. Ziel HK, Finkle WD Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975, 293:1167.
114. Archer DF, Pickar JH, Bottiglioni F, et al. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Am J Obstet Gynecol 1994, 83:686.
115. Bain C, Willett W, Hennekens CH, et al. Use of postmenopausal hormones and risk of myocardial infarction. Circulation 1981, 64:42.
116. Jensen J, Riis BJ, Strom V, et al. Continuous oestrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol 1987, 94:130.
117. PEPI trial writing group: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273:199, 1995.
118. Prough SG, Aksel S, Wiebe RH, et al. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987, 157:1449.
119. Sherwin BB, Gelfand MM A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol 1989, 73:759.
120. Weinstein L Efficacy of a continuous estrogen-progestin regimen in the postmenopausal patient. Obstet Gynecol 1987, 69:929.
121. Whitehead MI, McQueen J, Beard RJ, et al. The effects of cyclical oestrogen and sequential oestrogen progestogen therapy on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand Suppl 1977, 65:91.
122. Whitehead MI, Siddle N, Lane G, et al. The pharmacology of progestogens. Menopause: Physiology and Pharmacology 1987, CV Mosby, St. Louis. D.R. Mishell (Ed.).
123. Barrett-Connor E, Grady D Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998, 19:55.
124. Bergkvist L, Adami HO, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989, 130:221.
125. Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989, 5:293.
126. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995, 85:11.
127. Brewster WR, DiSaia PJ, McGonigle FK, et al. An experience of estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med 1999, 44:186.
128. Brinton LA, Hoover R, Fraumeni JF Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986, 54:825.
129. Calle EE, Miracle-McMahill HL, Thun MJ, et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995, 87:517.
130. Clinical Synthesis Panel on HRT Hormone replacement therapy. Lancet 1999, 354:152.
131. Colditz GA, Walter BS, Willett C, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987, 316:1105.
132. Colditz GA, Egan KM, Stampfer MJ, et al. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993, 168:173.
133. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332:1589.
134. Colditz GA, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992, 3:433.
135. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996, 347:1713.
136. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350:1047.
137. Cooper DR, Butterfield J Pregnancy subsequent to mastectomy for cancer of the breast. Ann Surg 1970, 171:429.
138. Creasman WT Is there an association between hormone replacement therapy and breast cancer?. J Women's Health Gend Based Med 1998, 7:1231.
139. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348:977.
140. Dew J, Eden J, et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998, 1:137.
141. DiSaia PJ Hormone replacement therapy in patients with breast cancer: a reappraisal. Cancer 1993, 71:1490.
142. DiSaia PJ, et al. Hormone replace therapy in breast cancer (Letter). Lancet 1993, 232:342.
143. DiSaia PJ, et al. Replacement therapy for breast cancer survivors: a pilot study. Cancer 1995, 476:10.
144. Dupont WD, Page DL Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991, 151:67.
145. Dupont WD, Page DL Risk factors for breast cancers in women with proliferative breast disease. N Engl J Med 1985, 312:146.
146. DuPont WD, Page DL, et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 1999, 85:1277.
147. DuPont WD, Page DL, Rogers LW, et al. Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk. Cancer 1989, 63:948.
148. Eden JA Estrogen and the breast. Med J Aust 1992, 157:125.
149. Espie M, Gorins A, Perret F, et al. Hormone replacement therapy in patients treated for breast cancer. analysis of a cohort of 120 patients. Proc ASCO 1999, 18:2262.
150. Gambrell RD Role of hormones in the etiology and prevention of endometrial and breast cancer. Acta Obstet Gynecol Scand Suppl 1982, 106:37.
151. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and the risk of colorectal adenoma and cancer. Ann Intern Med 1998, 128:705.
152. Grodstein F, Newcomb PA, Stampfer MJ Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999, 106:574.
153. Grodstein F, Stampfer M, Colditz C, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997, 336:1769.
154. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of preliminary embolism in women. Lancet 1996, 398:983.
155. Grodstein F, Stampfer MJ, et al. Nurses' Health Study: postmenopausal estrogen and progestin use and risk of cardiovascular disease. N Engl J Med 1996, 335:453.
156. Grunfeld E Dhesy-Thaind S, Levine M for the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: Follow-up after treatment of breast cancer. Canadian Medical Assoc J 2005, 172:1319.
157. Holleb AI, Farrow JH The relation of carcinoma of the breast and pregnancy in 283 patients. Surg Gynecol Obstet 1962, 115:65.
158. Holli K, Isola J, Cuzick J Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998, 16:1315.
159. Holmberg L, Anderson H, et al. HABITS (hormonal replacement therapy after breast cancer: is it safe?) a randomized comparison-trial stopped. Lancet 2004, 363:453.
160. Holmberg L, Iversen OE, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008, 100:475.
161. Hoover R, Gray LA, Cole P, et al. Menopausal estrogens and breast cancer. N Engl J Med 1976, 295:401.
162. Hulka BS Hormone replacement therapy and the risk of breast cancer. Cancer 1990, 40:289.
163. Ingle JN, Ahmann DI, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981, 304:16.
164. Kaufman DW, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991, 134:1375.
165. Korenman SG The endocrinology of breast cancer. Cancer 1980, 46:874.
166. Manson JE, Allison MA, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007, 356:2591.
167. Marsden J Hormone replacement therapy and breast cancer. Lancet Oncol 2002, 3:303.
168. Mendelsohn ME, Karas RH The protective effect of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801.
169. Mignot L, Morvan F, Berdah J, et al. Pregnancy after breast cancer: results of a case study. Presse Med 1986, 15:1961.
170. Nachtigall LE, et al. Estrogen replacement therapy. II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979, 54:74.
171. O'Meara ES, Rossing MA, et al. Hormone replacement after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl. Cancer Inst 2001, 93:754.
172. Paganini-Hill A Estrogen replacement therapy and stroke. Progr Cardiovas Dis 1995, 38:223.
173. Palmer JR, et al. Breast cancer risk after estrogen replacement therapy: results from the Toronto breast cancer study. Am J Epidemiol 1991, 134:1386.
174. Persson I, et al. Combined oestrogen-progestogen replacement and breast cancer risk. Lancet 1992, 340:1044.
175. Rosner D, Lane W Oral contraceptives use has no adverse effect on the prognosis of breast cancer. Cancer 1986, 57:591.
176. Rossouw JE, Prentice RL, et al. Postmenopausal hormone therapy and the risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297:1465.
177. Sellers TA, Mink PJ, Cerban JR, et al. The role of HRT in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997, 127:973.
178. Sillero-Arenas M, et al. Menopausal hormone treatment therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992, 79:286.
179. Stanford JL, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995, 274:137.
180. Steinberg KK, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991, 265:1985.
181. Strickland DM, et al. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992, 80:400.
182. Sullivan JM, Vander Zwagg R, et al. Estrogen replacement and coronary artery disease. Arch Intern Med 1990, 150:2557.
183. Vickers MR, MacLennan AH, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomized controlled trial of hormone replacement in postmenopausal women. BMJ 2007, 335:239.
184. Villarino CB, Fenster PE Coronary heart disease. Prim Care Update Ob/Gyn 1994, 1:150.
185. von Schoultz E, Rutqvist LE, et al. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005, 97:533.
186. Wile AG, DiSaia PJ Hormones and breast cancer. Am J Surg 1989, 157:438.
187. Willis DB, Calle EE, et al. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the U.S. Cancer Causes Control 1996, 7:449.
188. Wolf PH, Madans JH, et al. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones. Am J Obstet Gynecol 1991, 164:489.
189. Bain C, et al. Use of postmenopausal hormones and risk of myocardial infarction. Circulation 1981, 64:42.
190. Barnes RB, Roy S, Lobo RA Comparison of lipid and androgen levels after conjugated estrogens or depomedroxyprogesterone acetate treatment in postmenopausal women. Obstet Gynecol 1985, 66:216.
191. Bass KM Plasma lipoproteins as predictors of cardiovascular death in women. Arch Intern Med 1993, 153:2209.
192. Bush TL, Barrett-Conner E, Cowan LD, et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987, 75:1102.
193. Bush TL, Cowan LD, Barrett-Conner E, et al. Estrogen use and all-cause mortality: preliminary results from the Lipid Research Clinics Program Follow-up Study. JAMA 1983, 1:249.
194. Christiansen C, Lindsay R Estrogens, bone loss and preservation. Osteoporosis Int 1990, 1:7.
195. Corson SL Impact of estrogen replacement therapy on cardiovascular risk. J Reprod Med 1989, 34:729.
196. Davis SR, Moreau M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008, 359(19):2005.
197. Delellis Henderson K, Duan L, et al. Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiology 2010, 171(4):415.
198. Erenus M, et al. Comparison of the impact of oral vs. transdermal estrogen on serum lipoproteins. Fertil Steril 1994, 61:300.
199. Gambrell RD The menopause: Benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 1982, 37:457.
200. Gambrell RD, Teran AZ Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol 1991, 165:307.
201. Gordon GS, Picchi J, Roof BS Antifracture efficacy of long-term estrogens for osteoporosis. Trans Assoc Am Physicians 1973, 86:326.
202. Gordon T, et al. Menopause and coronary heart disease. Ann Intern Med 1978, 89:157.
203. Hammond CB, et al. Effects of long-term estrogen replacement therapy. I: Metabolic effects. Am J Obstet Gynecol 1979, 133:525.
204. Hunt K, Vessey M, McPherson K Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990, 97:1080.
205. Knopp RH The effect of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet Gynecol 1988, 72:23S.
206. La Rosa JC Estrogen: Risk vs. benefit for the prevention of coronary artery disease. Coron Artery Dis 1993, 4:588.
207. La Rosa JC The varying effects of progestins on lipid levels and cardiovascular disease. Am J Obstet Gynecol 1988, 158:1621.
208. Lindsay R, et al. Long-term prevention of post-menopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976, 1:1038.
209. Lobo RA Estrogen and cardiovascular disease. N Y Acad Sci 1990, 592:286.
210. Lobo RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogens therapy in postmenopausal women. Obstet Gynecol 1994, 84:987.
211. Lufkin EG, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117:1.
212. Magliano DJ, Rogers SL, et al. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006, 113(1):5.
213. Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989, 321:641.
214. Meema S, Bunker ML, Meema HE Preventive effect of estrogen on postmenopausal bone loss: A follow-up study. Arch Intern Med 1975, 135:1436.
215. Mendoza S, et al. Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein (a). J Lab Clin Med 1994, 123:837.
216. Newcomb PA, Zheng Y, et al. Estrogen plus progestin use, microsatellite instability and risk of colorectal cancer in women. Cancer Res. 2007, 67(15):7534.
217. Pfeffer RI, van den Noort S Estrogen use and stroke in postmenopausal women. Am J Epidemiol 1976, 103:445.
218. Ross RK, Paganini-Hill A, Mack TM, et al. Cardiovascular benefits of estrogen replacement therapy. Am J Obstet Gynecol 1989, 160:1301.
219. Ross RK, et al. Menopausal oestrogen therapy and protection from death from ischemic heart disease. Lancet 1981, 1:858.
220. Selby PL, Peacock M The effect of transdermal oestrogen on bone, calcium-regulating hormones and liver in postmenopausal women. Clin Endocrinol 1986, 25:543.
221. Stampfer MJ, Colditz GW Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47.
222. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of postmenopausal estrogen therapy and cardiovascular diseases: A ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991, 325:756.
223. Stampfer MJ, Colditz GW, Willett WC, et al. Menopause and heart disease: A review. Ann N Y Acad Sci 1990, 592:193.
224. Stampfer MJ, Sacks F, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991, 325:373.
225. Stampfer MJ, Willett WC, Colditz GW, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985, 313:1044.
226. Sullivan JM, Zwaag RV, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988, 108:358.
227. Whitehead MI Effects of hormone replacement therapy on cardiovascular disease: An interview. Am J Obstet Gynecol 1987, 69:929.
228. Wilson PWF, Garrison R, Castelli WP Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. N Engl J Med 1985, 313:1038.
229. Adami HO, Bergstrom R, Holmberg L, et al. The effect of female sex hormones on cancer survival. JAMA 1990, 263:2189.
230. Gambrell RD, Massey FM, Castaneda TA, et al. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980, 55:732.
231. Henderson BE, Paganini-Hill A, Ross RK Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991, 151:75.
232. Henderson BE, Ross RK, Lobo RA, et al. Reevaluating the role of progestogen therapy after the menopause. Fertil Steril 1988, 49:9S.
233. Mishell DR, Shoupe D, Moyer DL, et al. Postmenopausal hormone replacement with a combination estrogen-progestin regimen for five days per week. J Reprod Med 1991, 36:351.
234. Steinberg KK, Thacker SB, Smith J, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991, 265:1985.